

PERSONAL INFORMATION **Fei Fei****WORK EXPERIENCE**

October 2018–Present **Clinical Assessor**
AFMPS (Belgium)

May 2017–September 2018 **Medical Consultant**
BELSASS (Belgium)

September 2005–May 2017 **Medical Oncologist**
Shanghai Cancer Center Fudan University (China)

EDUCATION AND TRAINING

September 2010–December 2017 **PHD**
Fudan University (China)

September 2012–July 2014 **Fellowship**
EORTC Headquarter (Belgium)

September 2005–July 2009 **MD**
Fudan University (China)

September 2002–July 2005 **Master**
Fudan Univeristy (China)

September 1997–July 2002 **Bachelor**
Fudan Univeristy (China)

ADDITIONAL INFORMATION**Expertise****ACADEMIC CONFERENCE POSTER**

- 1 ASCO 2009 Abstract 11046
- 2 National Breast Cancer Conference 2007
- 3 CSCO 2007 E II003
- 4 Miami Breast Cancer Conference 2009 Abstract for Best 3
- 5 2010 IMPAKT Breast Cancer Conference78P
- 6 2011 St. Gallen Breast Cancer Symposium P300
- 7 2011 IMPAKT Breast Cancer Conference112P
- 8 2012 ESMO 666
- 9 2013 St. Gallen Breast Cancer Symposium P75,76
- 10 2014 EBCC-9 36
- 11 2015 IMPAKT Breast Cancer Conference 51P

HONORS

2009 Miami Breast Cancer Conference Top 3 Prize for composition

2010 IMPAKT Breast Cancer Conference Young Oncologist Travel Grant
2010 Eurasia-Pacific Scholarship
2011 St. Gallen Breast Cancer Symposium Young Oncologist Travel Grant
2011 IMPAKT Breast Cancer Conference Young Oncologist Travel Grant
2012-2014 EORTC Clinical Research Fellowship (FOCA) 2014 Signalling Pathways in Cancer
2014: Targeting the PI3K/AKT/mTOR pathway Travel Grant
2015 IMPAKT Breast Cancer Conference Young Oncologist Travel Grant
2015 Signalling Pathways in Cancer 2015 Travel Grant

PROFESSIONAL TRAINING

1 July 2006 APOHA Training Taipei, China
2 Feb 2006 Clinical Trial Training (Design) Thailand
3 April 2008 GCP Training Shanghai, China
4 May 2010 IMPAKT training course for early-career oncologists Brussels, Belgium
5 May 2011 IMPAKT training course for early-career oncologists Brussels, Belgium
6 March 2011—July 2011 General Hospital Wien Medical University (AKH) Clinical training and Lab Research Vienna, Austria
7 September 2012—July 2014 EORTC Headquarter Medical Fellow training for methodology on cancer clinical trials Brussels, Belgium
8 December 2012 Methodology of Clinical Trails Brussels, Belgium
9 June 2013 FLIMS Workshop on Methods in Clinical Cancer Research Switzerland
10 May 2015 IMPAKT training course for early-career oncologists Brussels, Belgium

Publications

PUBLICATIONS

1 Identification of breast cancer metastasis-associated proteins in an isogenic tumor metastasis model using two-dimensional gel electrophoresis and liquid chromatography-ion trap-mass spectrometry *Proteomics* 2006(6):3352-3368
2 Tumour size is the only predictive factor of distant recurrence after pathological complete response (pCR) to neoadjuvant chemotherapy in patients with large operable or locally advanced breast cancers: a sub-study of EORTC 10994/BIG-001 Phase III Trial *Eur J Cancer*. 2015 Feb;51(3):301-9
3 Efficacy and Safety of Docetaxel combined with Oxaliplatin as neoadjuvant chemotherapy regimen for Chinese triple negative local advanced breast cancer patients—A prospective, open and unicentric phase II clinical trial *American Journal of Clinical Oncology* 2013 36(6):545-551
4 Are changes in circulating tumor cell (CTC) count associated with the response to neoadjuvant chemotherapy in local advanced breast cancer? A meta-analysis *Oncology Research and Treatment (formerly Onkologie)* 2014;37(5):250-4.
5 Triple negative breast cancer (TNBC) patients diagnosed at different age present similar clinicopathological features, but different treatment and prognosis in Chinese population. *J Geriatr Oncol*. 2014 Jul;5 Suppl 1:S9.
6 Luteal versus follicular phase surgical oophorectomy plus tamoxifen in premenopausal women with metastatic hormone receptor-positive breast cancer. *Eur J Cancer*. 2016 Jun;60:107-16.
7 Suberoyl bis-hydroxamic acid induces p53-dependent apoptosis of MCF-7 breast cancer cells *Acta Pharmacol Sin*. 2008 Dec;29(12):1459-66. (first co-author)
8 Gene Expression Profiling in Apoptotic K562 Cells Treated by Homoharringtonine *Acta Biochimica et Biophysica Sinica* 2007;39(12)
9 A Multicentric Prospective Study of the Effect of Neoadjuvant Chemotherapy with Cyclophosphamide, Fluorouracil and Pirarubicin on Local Advanced Breast Cancer *Chinese Journal of Clinical Oncology* 2009 36(10):564-567

Projects

CLINICAL TRIAL

1 2003 ZOFAS T Novartis
2 2003 ML17746 Roche , HERA Roche
3 2005 I02110 University of Wisconsin

4 2005 CA201 ABI

5 2006 phase II clinical trial by CTF as neoadjuvant chemotherapy regimen for local advanced breast cancer patients (National Multicentric Clinical Trial)

6 2008 TAX625 Sanofi-Aventis

7 2009 OCD-200901(CTCs) Johnson&Johnson

8 2010 NCT01216111A Prospective, Randomized, Open-label, Multicentric, phase III Clinical Trial Compared With PC and CEF100 Followed by Docetaxel as Adjuvant Chemotherapy Regimen for Chinese Primary Triple Negative Breast Cancer Patients (National Multicentric Clinical Trial)

9 2010 NCT01216124 A Prospective, Open and Unicentric Phase II Clinical Trial of Docetaxel Combined With Oxaliplatin for Triple Negative Local Advanced Breast Cancer Patients (TNLABC) (National Unicentric Clinical Trial)

10 2012-2014 EORTC 10085 MALE BC, 10041 MINDACT, 10054 LAPATAX, OCCAM EORTC Headquarter

Memberships

ESMO – since 2009

ASCO – since 2009

CSCO– since 2007

ESSO-since 2014

Young BCG EORTC-since 2013

Other Relevant Information